Compare Adaptive Biotechnologies Corp (ADPT) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Chevron Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Chevron Corp trades at $175.91 (market cap $346.56B). The key difference: Chevron Corp is far larger — about 104.1× Adaptive Biotechnologies Corp's market cap, and Chevron Corp pays a 4.09% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CVX | |
|---|---|---|
Market Cap | $3.33B | $346.56B |
Sector | Health | Energy |
52-Week High | $22.37 | $211.14 |
52-Week Low | $10.24 | $146.72 |
Enterprise Value | $3.19B | $386.66B |
Volume | — | 9,807,834 |
Dividend Yield | — | 4.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Chevron (CVX) trades at $168.1, down 0.66% on the day, amid a broader technical bearish signal. The stock shows mixed fundamentals with declining revenue and net income over recent years, though it has consistently beaten earnings expectations. A strong $1.78 dividend is scheduled for payment in June 2026. Wall Street sentiment remains predominantly bullish, with a consensus price target of $209 representing significant upside, countering the current technical weakness.
The investment case balances a high analyst buy rating and attractive dividend against fundamental profit margin compression and exposure to volatile oil prices. Key risks include execution of major projects like the $13.8B Argentina investment and geopolitical tensions affecting supply chains. The stock's current price sits near immediate technical support at $167.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
